Obesity News

Adults with a mental illness experienced weight loss and glycemic benefits with use of a GLP-1 without worsening of mental health outcomes, according to a presenter at the European Congress on Obesity.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the SURMOUNT-5 trial.

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European Congress on Obesity.

Excess weight and obesity were significantly associated with long COVID-related neurological and neuropsychiatric symptoms, a systematic review and meta-analysis showed.

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, OB/GYNs and other specialists report observing fertility-related benefits that may accompany potent weight loss.

NATIONAL HARBOR, Md. — Navigating ineffective weight management treatment is a sensitive process that requires acknowledgement of bias from both patients and providers, according to presenters here.

NATIONAL HARBOR, Md. — Approaches to dietary interventions among patients with obesity can differ depending on whether they are also being treated with a GLP-1 receptor agonist, according to a speaker.

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic dysfunction-associated steatohepatitis and moderate or advanced liver fibrosis, researchers reported.

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, including those under rheumatology umbrella.